Chang Tsi & Partners has been recognized at the GIPC 2026 · Global Intellectual Property Conference Ecology, receiving the "TOP IPR CHINA Industry King Awards – Leading Life Sciences IP Litigation Firm" award. In addition, the firm's Partner Ryan Xu was honored with the "TOP IPR CHINA Industry King Awards – Leading Life Sciences IP Litigation Lawyer" award, recognizing his outstanding expertise and contributions in life sciences-related intellectual property disputes.

Organized by IPR Daily and IPR Daily Global, GIPC has become one of the most influential intellectual property industry platforms in the Asia-Pacific region since its establishment in 2015. The 2026 conference brought together IP authorities, corporate IP leaders, international patent organizations, law firms, and industry experts to discuss key trends shaping the future of IP development, including AI-driven IP transformation, life sciences IP value creation, and global SEP licensing strategies.

The recognition highlights Chang Tsi's growing strength in the life sciences and pharmaceutical IP sector. With a dedicated team of patent professionals, attorneys, and technical experts, Chang Tsi provides comprehensive IP services covering the entire lifecycle of innovation, including patent strategy, prosecution, invalidation, freedom-to-operate analysis, due diligence, licensing, and complex patent litigation.

Ryan Xu, Partner at Chang Tsi & Partners, specializes in patent litigation and complex IP disputes involving chemical, pharmaceutical, biotechnology, and engineering technologies. With a strong technical background and extensive experience in patent prosecution and litigation, Ryan has developed deep expertise in handling high-value patent disputes, invalidation proceedings, and strategic IP challenges.

The recognition at GIPC 2026 reflects Chang Tsi's continued commitment to advancing professional capabilities in emerging technology sectors and providing high-quality intellectual property solutions for innovative enterprises. Moving forward, Chang Tsi will continue to strengthen its expertise in life sciences and other strategic industries, delivering integrated and forward-looking IP services to clients worldwide.